Anti-hCD20 isotype collection
The Anti-hCD20 isotype collection features the variable region of rituximab. Rituximab is a mouse/human chimeric monoclonal antibody that targets the CD20 antigen found on the surface of malignant and normal B lymphocytes.
Binding of rituximab to CD20 results in cell destruction through different mechanisms including direct signaling of apoptosis, complement activation and cell-mediated cytotoxicity.
Rituximab has been approved by the FDA for the treatment of various lymphoid malignancies, including B-cell non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukaemia.
The anti-hCD20 isotype collections has been generated by recombinant DNA technology. It has been produced in CHO cells and purified by different types of affinity chromatography: protein G for IgG isotypes, protein L for IgE and IgM, and peptide M for the human IgA isotypes.